Search
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalby the U.S. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved
Homatropine methylbromide
go.drugbank.com/drugs/DB00725ApprovedIt can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.
Deoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalIn April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical
Tividenofusp alfa
go.drugbank.com/drugs/DB17628ApprovedInvestigationalWhile standard ERTs can treat systemic symptoms, they are unable to cross the blood-brain barrier (BBB) to address the progressive cognitive decline and neurological impairment seen in the majority of … Developed by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099].
Elacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigationalElacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. … [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Medifoxamine
go.drugbank.com/drugs/DB13219ApprovedMedifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity
Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalPfizer is conducting an additional safety study of the drug, results of which are expected in late 2015.
Endometrial Carcinoma
go.drugbank.com/conditions/DBCOND0031833Synonyms: Ca endometrium, Endometrial CaTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion … [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018.